Cyclacel Pharmaceuticals Preferred Stock Performance
| CYCCP Preferred Stock | USD 5.80 0.04 0.69% |
The firm shows a Beta (market volatility) of -0.46, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Cyclacel Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Cyclacel Pharmaceuticals is likely to outperform the market. At this point, Cyclacel Pharmaceuticals has a negative expected return of -0.36%. Please make sure to confirm Cyclacel Pharmaceuticals' value at risk, and the relationship between the jensen alpha and accumulation distribution , to decide if Cyclacel Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Preferred Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 33.4 M | |
| Total Cashflows From Investing Activities | -27 K |
Cyclacel |
Cyclacel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 773.00 in Cyclacel Pharmaceuticals on September 15, 2024 and sell it today you would lose (193.00) from holding Cyclacel Pharmaceuticals or give up 24.97% of portfolio value over 90 days. Cyclacel Pharmaceuticals is currently producing negative expected returns and takes up 4.1361% volatility of returns over 90 trading days. Put another way, 36% of traded preferred stocks are less volatile than Cyclacel, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cyclacel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyclacel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of preferred stocks, such as Cyclacel Pharmaceuticals, and traders can use it to determine the average amount a Cyclacel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0876
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYCCP |
Estimated Market Risk
| 4.14 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.36 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cyclacel Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclacel Pharmaceuticals by adding Cyclacel Pharmaceuticals to a well-diversified portfolio.
Cyclacel Pharmaceuticals Fundamentals Growth
Cyclacel Preferred Stock prices reflect investors' perceptions of the future prospects and financial health of Cyclacel Pharmaceuticals, and Cyclacel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyclacel Preferred Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 24.42 M | ||||
| Shares Outstanding | 12.5 M | ||||
| Price To Earning | (2.62) X | ||||
| EBITDA | (15 M) | ||||
| Cash And Equivalents | 29.08 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 113 K | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 1.76 X | ||||
| Cash Flow From Operations | (18.54 M) | ||||
| Earnings Per Share | (2.05) X | ||||
| Total Asset | 42.59 M | ||||
About Cyclacel Pharmaceuticals Performance
Assessing Cyclacel Pharmaceuticals' fundamental ratios provides investors with valuable insights into Cyclacel Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cyclacel Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.Things to note about Cyclacel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cyclacel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Preferred Stock alerts and notifications screener for Cyclacel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyclacel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cyclacel Pharmaceuticals has high historical volatility and very poor performance | |
| Cyclacel Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (18.89 M) with loss before overhead, payroll, taxes, and interest of (338 K). | |
| Cyclacel Pharmaceuticals has accumulated about 29.08 M in cash with (18.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32. |
- Analyzing Cyclacel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyclacel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cyclacel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyclacel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyclacel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyclacel Pharmaceuticals' preferred stock. These opinions can provide insight into Cyclacel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cyclacel Preferred Stock Analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.